AMT
-
AMT Starts Development of LPLD Diagnostic Tool
Amsterdam Molecular Therapeutics (AMT) and Progenika Biopharma have entered into a development and commercialization agreement for LPLchip, a diagnostic tool to rapidly diagnose patients with complete and partial Lipoprotein Lipase Deficiency (LPLD).…
AMT | 13 November 2009
-
AMT Receives Orphan Drug Designation for DMD Treatment
Amsterdam Molecular Therapeutics (AMT) has announced that the European Medicines Agency (EMEA) has granted Orphan Drug Designation to the former’s gene therapy product AMT-080 for the treatment of Duchenne Muscular Dystrophy (DMD). Orphan Drug …
AMT | 22 October 2009
